DV Trading LLC Buys Shares of 1,400,000 Century Therapeutics, Inc. $IPSC

DV Trading LLC purchased a new position in Century Therapeutics, Inc. (NASDAQ:IPSC) during the 1st quarter, Holdings Channel reports. The institutional investor purchased 1,400,000 shares of the company’s stock, valued at approximately $3,164,000. Century Therapeutics accounts for about 0.1% of DV Trading LLC’s investment portfolio, making the stock its 23rd largest holding.

A number of other large investors have also made changes to their positions in IPSC. Quadrant Private Wealth Management LLC lifted its holdings in shares of Century Therapeutics by 31.0% during the 1st quarter. Quadrant Private Wealth Management LLC now owns 20,022 shares of the company’s stock valued at $45,000 after purchasing an additional 4,736 shares during the last quarter. Geode Capital Management LLC grew its stake in Century Therapeutics by 2.4% during the 4th quarter. Geode Capital Management LLC now owns 456,115 shares of the company’s stock worth $454,000 after buying an additional 10,806 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in Century Therapeutics during the 1st quarter worth $29,000. Bank of America Corp DE increased its position in Century Therapeutics by 109.1% during the 4th quarter. Bank of America Corp DE now owns 66,043 shares of the company’s stock valued at $67,000 after buying an additional 34,466 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its position in Century Therapeutics by 26.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 179,635 shares of the company’s stock valued at $86,000 after buying an additional 38,052 shares in the last quarter. 50.20% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on IPSC shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Century Therapeutics in a report on Thursday, July 2nd. Mizuho assumed coverage on shares of Century Therapeutics in a report on Wednesday, May 27th. They set an “outperform” rating and a $8.00 price objective on the stock. HC Wainwright increased their price objective on shares of Century Therapeutics from $2.00 to $5.00 and gave the company a “buy” rating in a research report on Tuesday, April 21st. Finally, Wall Street Zen lowered shares of Century Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 27th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Century Therapeutics presently has an average rating of “Hold” and an average price target of $4.75.

Century Therapeutics Price Performance

Shares of IPSC opened at $2.02 on Friday. The company’s fifty day moving average price is $2.25 and its 200-day moving average price is $2.23. Century Therapeutics, Inc. has a 1-year low of $0.44 and a 1-year high of $3.04. The firm has a market capitalization of $364.31 million, a PE ratio of -1.77 and a beta of 1.55.

Century Therapeutics (NASDAQ:IPSC) last issued its earnings results on Wednesday, May 13th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.04. As a group, research analysts anticipate that Century Therapeutics, Inc. will post -0.43 EPS for the current fiscal year.

Century Therapeutics Company Profile

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.